Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech's biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom and Japan. In combination with the previously announced agreement which granted a Q4 2026 license entry date for the U.S., pending regulatory approval, Alvotech now has worldwide rights to manufacture and supply its global commercial partners with the aflibercept biosimilar. The settlement agreement allows Alvotech and its commercial partners to market and sell the biosimilar as of January 1, 2026 in the United Kingdom and Canada, as well as in Japan (excluding the diabetic macular edema indication) starting May 1, 2026 in the European Economic Area and all other countries in the world (other than the U.S.), and from November 1, 2026 in
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech (ALVO) had its price target lowered by UBS Group AG from $10.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Alvotech (ALVO) had its price target lowered by Barclays PLC from $5.00 to $4.00. They now have an "underweight" rating on the stock.MarketBeat
- Alvotech (ALVO) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Did Alvotech's (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative? [Yahoo! Finance]Yahoo! Finance
- Alvotech (ALVO) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 11/12/25 - Beat
ALVO
Sec Filings
- 3/19/26 - Form 6-K
- 3/12/26 - Form SCHEDULE
- 2/27/26 - Form 6-K
- ALVO's page on the SEC website